The current guideline provides conditional recommendations (1.2.1 and 1.5.1) that vorasidenib may be offered to patients with grade 2 IDH-mutant oligodendrogliomas where, after one or more surgeries, further treatment with radiation and chemotherapy has been or can be deferred [21]. This evidence concerns the gene IDH2 and oligodendroglioma.